公司动态 - 公司将于2025年3月13日美国东部时间下午5点/太平洋时间下午2点举行电话会议和网络直播，公布2024年第四季度及全年财务业绩并提供公司最新动态 [1] - 电话会议和网络直播详情包括日期、时间、拨入注册链接和网络直播注册链接 [2] - 参与者需通过指定链接注册电话会议以获取拨入号码和个人PIN码，或通过公司投资者关系页面访问网络直播 [2] 公司概况 - 公司是一家临床阶段生物技术公司，专注于利用tRNA合成酶生物学开发治疗纤维化和炎症的首创药物 [3] - tRNA合成酶是古老的必需蛋白质，在人类细胞外调控多种通路，公司通过其专有的20种tRNA合成酶衍生结构域库发现新的治疗干预点 [3] - 公司主要候选药物efzofitimod是一种首创生物免疫调节剂，正在开发用于治疗间质性肺病，该疾病可导致肺部炎症和进行性纤维化 [3]

公司动态 - 公司将在2025年3月9日至12日参加Leerink Partners全球医疗保健会议 [1] - 公司总裁兼首席执行官Sanjay S Shukla博士将于2025年3月10日下午1:40进行炉边谈话 [1] - 会议期间公司管理层将与注册投资者进行一对一会议 [1] - 演讲内容将在公司官网投资者关系板块进行网络直播 [1] - 演讲录像将在公司官网保留至少90天 [1] 公司概况 - 公司是一家临床阶段生物技术公司 [2] - 专注于利用tRNA合成酶生物学开发纤维化和炎症新疗法 [2] - tRNA合成酶是古老的必需蛋白质 [2] - 公司发现平台专注于从其专有的20种tRNA合成酶衍生库中寻找新的治疗干预点 [2] - 主要候选药物efzofitimod是一种首创生物免疫调节剂 [2] - efzofitimod正在开发用于治疗间质性肺病 [2] 联系方式 - 投资者关系高级总监Ashlee Dunston负责联系事宜 [3]

文章核心观点 aTyr Pharma公司将在2025年美国胸科学会国际会议上展示其主要治疗候选药物efzofitimod的三张海报，该公司正在对efzofitimod进行多项临床试验研究 [1] 公司信息 - aTyr是临床阶段生物技术公司，利用进化智能将tRNA合成酶生物学转化为治疗纤维化和炎症的新疗法，其发现平台专注于解锁隐藏治疗干预点，主要治疗候选药物是efzofitimod [4] - 公司联系方式为投资者关系和公共事务高级总监Ashlee Dunston，邮箱adunston@atyrpharma.com [7] 药物信息 - efzofitimod是一流的生物免疫调节剂，正在进行治疗间质性肺病的临床开发，通过神经纤毛蛋白 - 2选择性调节活化的髓样细胞以解决炎症，且不抑制免疫并可能预防纤维化进展 [3] - 公司正在对efzofitimod进行两项研究，分别是针对肺结节病患者的全球3期EFZO - FIT™研究和针对系统性硬化症相关间质性肺病患者的2期EFZO - CONNECT™研究 [3] 海报信息 - 海报标题为“EFZO - FIT, Largest Placebo - Controlled Trial in Pulmonary Sarcoidosis – Trial Design and Patient Characteristics”，展示时间为2025年5月19日9:15AM – 4:15PM PT，地点在旧金山Moscone中心，所属会议环节为“Repair My Broken Lungs” [2] - 海报标题为“Real - World Treatment Patterns Among Pulmonary Sarcoidosis Patients with Parenchymal Involvement in the US”，展示时间为2025年5月18日9:15AM – 4:15PM PT，地点在旧金山Moscone中心，所属会议环节为“The Inflamed Lung: Sarcoidosis and Autoimmune Disease” [2] - 海报标题为“Incidence, Prevalence, and Mortality of Pulmonary Sarcoidosis with Parenchymal Involvement in the US”，展示时间为2025年5月20日9:15AM – 4:15PM PT，地点在旧金山Moscone中心，所属会议环节为“Current Insights into Risk, Diagnosis, and Treatment of Occupational and Environmental Lung Diseases” [2] 研究进展 - EFZO - FIT™研究的基线人口统计学和疾病特征已设盲，预计2025年第三季度公布该研究的 topline 数据 [1]

SAN DIEGO, Dec. 17, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference, which is scheduled to take place January 13 – 16, 2025, in San Francisco, CA. Details of the presentation appear below: C ...

SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Eric Benevich to the Company’s Board of Directors, effective as of December 10, 2024. Mr. Benevich currently serves as Chief Commercial Officer at Neurocrine Biosciences, Inc. (Neurocrine). “We are excited to welcome ...

SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Company will present two posters related to its tRNA synthetase candidate ATYR0101 at the Keystone Symposia on Fibrosis: Inflammation, Drivers, and Therapeutic Resolution, which is scheduled to take place December 8 – 11, 2024, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37378 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 20-3435077 (State or other jurisdic ...

Exhibit 99.1 IMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update Enrollment completed in Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline data expected in the third quarter of 2025. Publication in European Respiratory Journal demonstrated statistically significant difference in time-to-first relapse for corticosteroid use and improvement in cort ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37378 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 20-3435077 (State or other jurisdiction ...

Exhibit 99.1 IMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis enrollment completed with 268 patients; topline data from this 52-week study expected in the third quarter of 2025. Ended the second quarter 2024 with $81.4 million in cash, cash equivalents, restricted cash and investments. SAN DIEGO – Augu ...